Investors Hub Daily
|
Home
|
Log in
Boards
Stocks
Commodities
Forex
The Lounge
Hot!
Breakout Boards
iHub My Stocks Activity
Ticker Buzz Cloud
Top Boards
Most Read
Most Posted
Most Followed Members
Recent News
Active Boards
Site Stats
New Boards
Hot on StockWiki
Data Tools
Charts
Trader Alerts
Trades
Portfolio
Top Lists
News Alerts
Commodities
More Tools
My Image Gallery
Advanced Search
Videos
All News
Stock Screener
News Filter
Live Charts
Live News
Live Desktop
Forex Prices
Commodities
ETF Center
Online Brokers
Educational Channel
Streamer
Level 2
Home
>
Boards
>
US Listed
>
Biotechs
>
Arena Pharmaceuticals, Inc. (ARNA)
check this link out. Good news for
Public Reply
|
Private Reply
|
Keep
|
Last Read
Post New Msg
Next 10
|
Previous
|
Next
Crazyjake27
Monday, July 23, 2012 8:21:35 PM
Re:
None
Post #
of
18451
check this link out. Good news for Arena. I can see a better chance for a buyout. They will want a new drug worth multi billions in there pipeline.
http://ih.advfn.com/p.php?pid=nmona&article=53564846
Pfizer Says Alzheimer's Drug Study Fails to Reach Goa
ls
Print
Pfizer (NYSE:PFE)
Intraday Stock Chart
Today : Monday 23 July 2012
Pfizer Inc. (PFE) said its bapineuzumab, a highly anticipated potential treatment for Alzheimer's disease, failed to reach its set goals in its first of four Phase 3 studies.
Drug makers including Pfizer, Johnson & Johnson (JNJ) and Eli Lilly & Co. (LLY) are spending millions to find the first treatment to address the underlying mechanisms of Alzheimer's, a form of dementia that progressively robs patients of their memories and affects their thinking and behavior.
Pfizer, which partnered with Janssen Alzheimer Immunotherapy R&D LLC to develop an Alzheimer's drug, said all other ongoing bapineuzumab studies are continuing without changes.
Other study results should be reported later this summer, Pfizer said.
The company said it was disappointed with the results, but added that a more complete understanding of its drug and its potential in patients with mild-to-moderate Alzheimer's will come from the additional studies.
Pfizer in May reported that its first-quarter earnings fell 19% during the first full quarter since its blockbuster cholesterol drug Lipitor lost market exclusivity last year. The company is expected to report its second-quarter financial results on July 31.
Pfizer's shares slipped 0.6% after hours to $23.46, while smaller rival Eli Lilly's fell 1.9% to $43. J&J was down 0.5% at $67.77.
-Write to Ben Fox Rubin at ben.rubin@dowjones.com
Subscribe to WSJ:
http://online.wsj.com?mod=djnwires
LONG ARNA>
Please do your own dd before you invest.
Arena Pharmaceuticals, Inc. (ARNA) Stock Trading Info:
Public Reply
|
Private Reply
|
Keep
|
Last Read
Post New Msg
Next 10
|
Previous
|
Next
Follow Board
Keyboard Shortcuts
Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote
-
Discussion Board
+/- to Watchlist
© 2013 InvestorsHub.Com, Inc.